Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARF6 | P62330 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 10/20 | 0.40 |
| ▸ | CNR2 | P34972 | 8/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | MAT2A | P31153 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3556439 | 0.88 | CNR1 (0.40) | ARF6CNR1CNR2LRRK2CHRM5 | |
| SCHEMBL14280867 | 0.87 | CNR1 (0.41) | ARF6CNR1CNR2 | |
| SCHEMBL4872141 | 0.82 | AVPR2 (0.45) | CNR1CNR2CHRM5CHRM3CA12 | |
| SCHEMBL3552729 | 0.80 | CNR1 (0.44) | CNR1CNR2MAPTMALT1 | |
| SCHEMBL3551780 | 0.79 | MET (0.41) | CNR1CNR2TP53 | |
| SCHEMBL3551748 | 0.79 | TACR1 (0.46) | CNR1 | |
| SCHEMBL13593482 | 0.77 | LRRK2 (0.38) | CNR1CNR2LRRK2MAOBTP53 | |
| SCHEMBL13593484 | 0.76 | DGAT2 (0.40) | CNR1CNR2LRRK2MALT1 | |
| SCHEMBL3557048 | 0.76 | ALOX5 (0.45) | ARF6CNR1CNR2TP53 | |
| SCHEMBL4872815 | 0.76 | CNR1 (0.43) | CNR1CNR2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7317012-B2 | Bicyclic heterocycles as cannabinoind-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-08 | — | — | US | disclosed |
| US-7317012-B2 | Bicyclic heterocycles as cannabinoind-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-08 | — | — | US | disclosed |
| US-7317012-B2 | Bicyclic heterocycles as cannabinoind-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-08 | — | — | US | disclosed |
| US-20060287322-A1 | Bicyclic heterocycles as cannabinoind-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287322-A1 | Bicyclic heterocycles as cannabinoind-1 receptor modulators | CNR1, CNR2, GPR18 | ARF6 1912/4885CNR1 1/4885CNR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.